Dongbao Enterprise

Tonghua Dongbao is a leading Chinese biopharmaceutical company specializing in the research, development, and large-scale production of insulin and other metabolic treatments. Founded in 1985, the company achieved significant prominence as the first Chinese enterprise to develop and commercialize recombinant human insulin, marketed under the brand name Gansulin. Its extensive product portfolio includes second-generation human insulin and third-generation insulin analogues such as insulin aspart, insulin glargine, and insulin lispro. Beyond its core insulin business, Tonghua Dongbao is aggressively expanding its pipeline into GLP-1 receptor agonists, SGLT2 inhibitors, and treatments for gout and hyperuricemia. The company maintains a dominant market share in China and is increasingly focused on international expansion through strategic partnerships and global regulatory filings.